News for HUTCHMED (0013.HK)

Published at

Feb 2, 2023 4:25 PM

by seekingalpha.com

mixed

mixed

Structure Therapeutics Hopes To Wow Investors With Cutting-Edge Drug Tech (Pending:GPCR)

Structure Therapeutics is hoping to impress investors with its cutting-edge drugs, strong executive team and bi-continental China-U.S. organization

0013.HK GSK.L

Read more →
Published at

May 15, 2022 4:45 PM

by seekingalpha.com

negative

negative

Amid Slowing Sales At Home, Innovent Biologics Stumbles Overseas (IVBIY)

Innovent Biologics terminated a plan to sell its bevacizumab biosimilar in North America with a local partner after trials for the drug fell behind schedule.

IVBXF 1801.HK 0013.HK

Read more →
Published at

Mar 11, 2022 4:12 PM

by seekingalpha.com

mixed

mixed

Hutchmed (HCM) Roils Markets With Changing Of Its Guard, U.S. Delisting Threat

U.S. securities regulator says Hutchmed is one of five Chinese companies in danger of delisting, a week after company announced the retirement of its longtime CEO. Read more here.

HCM BGNEN.MX BGNE B1GN34.SA 6160.HK ZLAB HCM.L 9688.HK 0013.HK

Read more →